Acute Mesenteric Ischemia

Quick Answer

Acute mesenteric ischemia (AMI) is a life-threatening surgical emergency caused by inadequate blood flow to the intestines, presenting with the classic triad of severe abdominal pain out of proportion to physical findings, metabolic acidosis, and rapid clinical deterioration. The four main subtypes are superior mesenteric artery (SMA) embolism (50%), SMA thrombosis (15%), non-occlusive mesenteric ischemia (NOMI, 20%), and mesenteric venous thrombosis (MVT, 10%). Diagnosis relies on CT angiography with 93% sensitivity and 95% specificity. Management involves aggressive resuscitation, broad-spectrum antibiotics, systemic anticoagulation, and urgent revascularization via endovascular therapy or surgical exploration. Despite advances in diagnosis and treatment, mortality remains 50-70% when transmural infarction is present, highlighting the critical importance of early recognition and intervention.

---

CICM Exam Focus

What CICM Expects You to Know

Primary Examination (Written):

• Mesenteric vascular anatomy and collateral circulation
• Pathophysiology of ischemia-reperfusion injury
• Oxygen delivery and extraction in splanchnic circulation

Second Part Examination (Written \u0026 Viva):

• Classification of AMI and distinguishing features
• Diagnostic approach including biomarkers and imaging
• Management algorithms for different AMI subtypes
• Recognition of complications: bowel perforation, abdominal compartment syndrome, multi-organ failure
• NOMI-specific management in ICU patients
• Post-operative ICU care and prognostication

Hot Topics for Viva:

• "How would you manage a post-cardiac surgery patient with rising lactate and abdominal pain?"
• "Discuss the role of endovascular therapy versus open surgery"
• "What are the indications for second-look laparotomy?"
• "Describe your approach to NOMI in a vasopressor-dependent patient"

---

Key Points

Clinical Recognition

• Classic presentation: Pain out of proportion to physical findings (sensitivity 75-80%)
• Early phase: Severe periumbilical pain, vomiting, forced bowel evacuation
• Late phase: Bloody diarrhea, peritonitis, shock, multi-organ failure
• High-risk populations: Atrial fibrillation, recent MI, cardiac surgery, dialysis, critical illness

Classification (Pathophysiological)

1. SMA Embolism (50%): Embolic occlusion 3-10 cm distal to SMA origin
2. SMA Thrombosis (15%): Thrombotic occlusion at SMA origin (atherosclerotic)
3. NOMI (20%): Mesenteric vasoconstriction without organic occlusion
4. Mesenteric Venous Thrombosis (10%): Portal/mesenteric venous thrombus

Diagnostic Strategy

• Laboratory: Lactate elevation (late sign), leucocytosis, metabolic acidosis, elevated D-dimer (95% sensitivity)
• Imaging: CT angiography (gold standard: 93% sensitivity, 96% specificity)
• Red flags: Pneumatosis intestinalis, portal venous gas (indicate transmural necrosis)

Management Priorities

1. Resuscitation: Large-bore access, aggressive fluid resuscitation, vasopressor support if needed
2. Anticoagulation: Unfractionated heparin (unless contraindicated)
3. Antibiotics: Broad-spectrum coverage (piperacillin-tazobactam or meropenem)
4. Revascularization: Endovascular (first-line if stable) or open surgery (if peritonitis)
5. NOMI-specific: Optimize cardiac output, reduce vasopressors, intra-arterial papaverine
6. Surgery: Damage control laparotomy, resection of non-viable bowel, second-look at 24-48 hours

Prognostic Factors

• Time to treatment: Mortality \u003c30% if revascularized \u003c6 hours; \u003e80% if \u003e12 hours
• Bowel viability: 30-40% mortality without infarction; 50-70% with transmural infarction
• Age and comorbidity: Elderly, cardiac disease, renal failure have worse outcomes
• NOMI: Mortality 50-70% even with treatment

---

Epidemiology

Incidence

Acute mesenteric ischemia accounts for 1 in 1,000 acute hospital admissions and 0.1% of all emergency department presentations. The incidence is rising due to aging populations and increased prevalence of cardiovascular disease, with current estimates of 12.9 cases per 100,000 person-years in Western populations. ICU patients represent a unique high-risk cohort, with NOMI occurring in 0.3-1.2% of all ICU admissions and up to 8% of patients requiring high-dose vasopressor support.

Age and Sex Distribution

The mean age at presentation is 70-75 years, with 60-70% of cases occurring in patients over 70 years old. There is a slight female predominance (55-60% female), particularly in embolic AMI due to the higher prevalence of atrial fibrillation in elderly women. However, NOMI shows equal sex distribution and MVT demonstrates male predominance (60-70% male) due to higher rates of inherited thrombophilias in men.

Mortality

Despite advances in diagnosis and treatment, AMI remains one of the most lethal abdominal emergencies. Overall in-hospital mortality is 60-80%, with significant variation by subtype. Mortality is lowest in MVT (20-30% with early anticoagulation) and highest in NOMI (70-90%). The presence of bowel infarction increases mortality dramatically: from 30% without infarction to 70-80% with transmural necrosis. Early diagnosis and revascularization within 6 hours reduces mortality to 30-40%, but delays beyond 12 hours result in mortality exceeding 80%.

Risk Factors

Embolic AMI:

• Atrial fibrillation (60-80% of cases)
• Recent myocardial infarction with mural thrombus
• Valvular heart disease (mitral stenosis, prosthetic valves)
• Left ventricular thrombus (dilated cardiomyopathy)
• Paradoxical embolism (patent foramen ovale with DVT)
• Recent cardiac procedures (angiography, valvuloplasty)

Thrombotic AMI:

• Chronic mesenteric ischemia (90% have prior symptoms)
• Severe atherosclerotic disease (peripheral vascular, coronary)
• Vasculitis (polyarteritis nodosa, Takayasu arteritis)
• Aortic dissection or aneurysm
• Hyperviscosity syndromes (polycythemia vera)

NOMI:

• Cardiac surgery (especially cardiopulmonary bypass)
• Cardiogenic or hemorrhagic shock
• High-dose vasopressor therapy (noradrenaline \u003e0.3 mcg/kg/min)
• Dialysis (particularly during sessions)
• Dehydration and hypovolemia
• Cocaine or methamphetamine use
• Digoxin toxicity

Mesenteric Venous Thrombosis:

• Inherited thrombophilias (Factor V Leiden, prothrombin G20210A, protein C/S deficiency)
• Acquired hypercoagulable states (malignancy, antiphospholipid syndrome)
• Inflammatory bowel disease (Crohn's, ulcerative colitis)
• Pancreatitis
• Portal hypertension and cirrhosis
• Oral contraceptive use
• Recent abdominal surgery or trauma

---

Pathophysiology

Mesenteric Vascular Anatomy

The intestinal blood supply derives from three main vessels arising from the abdominal aorta: the celiac trunk (foregut), superior mesenteric artery (midgut), and inferior mesenteric artery (hindgut). The SMA is the most clinically significant vessel in AMI, supplying the entire small bowel from the distal duodenum to the proximal two-thirds of the colon.

The SMA originates from the anterior aorta at the L1 level, approximately 1 cm below the celiac trunk. Its first branches are the inferior pancreaticoduodenal artery and multiple jejunal and ileal branches, followed by the middle colic, right colic, and ileocolic arteries. This branching pattern creates watershed areas at the splenic flexure (Griffiths' point, between SMA and IMA) and the rectosigmoid junction (Sudeck's point, between IMA and internal iliac arteries), which are particularly vulnerable to ischemia.

Extensive collateral circulation exists between the three mesenteric vessels via the marginal artery of Drummond (connecting SMA and IMA along the colon) and the arc of Riolan (direct connection between SMA and IMA). These collaterals can provide protection in chronic mesenteric ischemia but are insufficient in acute occlusion.

Mechanisms of Ischemia by Subtype

SMA Embolism: Emboli typically lodge 3-10 cm distal to the SMA origin, beyond the origin of the middle colic artery but proximal to the jejunal branches. This spares the proximal jejunum and transverse colon while causing ischemia to the distal jejunum, ileum, and right colon. The embolic material is usually cardiac in origin (80-90%), consisting of left atrial thrombus in atrial fibrillation, mural thrombus post-MI, or valvular vegetations. The sudden complete occlusion does not allow time for collateral development, leading to rapid progression to infarction within 6-12 hours.

SMA Thrombosis: Thrombosis occurs at the SMA origin in patients with pre-existing severe atherosclerosis. Unlike embolism, these patients often have a history of chronic mesenteric ischemia (postprandial pain, food fear, weight loss) as collaterals develop over months to years. Acute thrombosis occurs when a critical stenosis (\u003e70%) progresses to complete occlusion, often triggered by hypotension, dehydration, or low cardiac output. The proximal occlusion affects a larger territory than embolism, including the entire small bowel and right colon, but collaterals may provide some protection initially.

Non-Occlusive Mesenteric Ischemia (NOMI): NOMI results from intense mesenteric vasoconstriction in the absence of anatomic occlusion. The pathophysiology involves a combination of systemic hypoperfusion (low cardiac output, hypovolemia) and compensatory splanchnic vasoconstriction mediated by the sympathetic nervous system, renin-angiotensin-aldosterone system, and exogenous vasopressors. The mesenteric arterioles undergo sustained vasospasm, reducing mucosal blood flow by 60-80% despite normal or near-normal central pressures. This creates a "vicious cycle" where ischemia causes local release of vasoconstrictors (endothelin, thromboxane) that perpetuate vasospasm even after the initial insult resolves. NOMI typically affects longer segments of bowel in a patchy distribution, with relative sparing of the colon.

Mesenteric Venous Thrombosis: MVT begins with thrombus formation in the smaller mesenteric veins, progressing to involve the larger venous arcades, mesenteric vein, and portal vein. Venous occlusion causes bowel wall edema, hemorrhage, and increased interstitial pressure, which secondarily compromises arterial inflow. The process evolves more slowly than arterial occlusion (days to weeks), allowing some adaptation. However, once arterial compromise occurs, progression to infarction accelerates. MVT typically affects segmental areas of bowel with sharp demarcation between ischemic and normal segments.

Ischemia-Reperfusion Injury

Successful revascularization paradoxically triggers a cascade of injury mechanisms that can worsen tissue damage and trigger systemic complications. During ischemia, cellular ATP depletion converts xanthine dehydrogenase to xanthine oxidase. Upon reperfusion, oxygen reintroduction allows xanthine oxidase to generate massive amounts of reactive oxygen species (superoxide, hydrogen peroxide, hydroxyl radicals) that overwhelm endogenous antioxidant defenses.

Simultaneously, reperfusion activates complement pathways (C3a, C5a), recruits neutrophils to the bowel wall, and triggers release of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8). Activated neutrophils release proteases and myeloperoxidase, causing direct endothelial damage and microvascular thrombosis. The damaged intestinal barrier allows translocation of bacteria and endotoxin into the portal and systemic circulation, triggering systemic inflammatory response syndrome (SIRS) and potentially multi-organ dysfunction syndrome (MODS).

Reperfusion injury can extend the zone of injury beyond the initial ischemic territory and cause remote organ damage to the lungs (acute respiratory distress syndrome), kidneys (acute tubular necrosis), and liver (hepatocellular injury). The severity of reperfusion injury correlates with the duration and completeness of the initial ischemic insult.

Stages of Intestinal Ischemia

Intestinal ischemia progresses through predictable histological stages:

Stage 1 (0-3 hours): Mucosal ischemia with villous tip necrosis and sloughing. The mucosa is most vulnerable due to high metabolic demand and countercurrent oxygen exchange in villi. Clinically, patients have severe pain but minimal physical findings. Bowel wall may appear grossly normal at laparotomy.

Stage 2 (3-6 hours): Transmural ischemia extending through submucosa into muscularis propria. Bowel wall edema develops, and hemorrhage appears in the submucosa. Clinically, bloody diarrhea may occur as sloughed mucosa is evacuated. Physical examination may reveal mild abdominal tenderness, but peritonitis is absent.

Stage 3 (6-12 hours): Full-thickness necrosis with potential perforation. The bowel wall becomes thin and friable (early) or thickened and dusky (late). Serosal surface shows hemorrhage and fibrinous exudate. Clinically, peritonitis develops with rebound tenderness, guarding, and absent bowel sounds.

Stage 4 (\u003e12 hours): Frank gangrene with perforation, peritonitis, and septic shock. The bowel is black, non-viable, and friable. Pneumatosis intestinalis and portal venous gas indicate bacterial translocation through the dead bowel wall. Mortality exceeds 80% at this stage despite aggressive intervention.

---

Clinical Presentation

Classic Triad

The pathognomonic presentation of AMI consists of:

1. Severe abdominal pain out of proportion to physical findings (75-80% of cases)
2. Rapid onset (minutes to hours in embolic; hours to days in thrombotic/MVT)
3. High-risk patient profile (elderly, cardiovascular disease, arrhythmia)

Symptom Progression

Embolic AMI (acute onset, minutes to hours):

• Sudden severe periumbilical or epigastric pain
• Nausea and vomiting (70-80%)
• Urgent bowel evacuation ("cathartic" diarrhea) in 30-50%
• Pain initially colicky, becoming constant
• Minimal abdominal tenderness early despite severe pain

Thrombotic AMI (subacute onset, hours to days):

• History of chronic mesenteric ischemia in 70-90% (postprandial pain, food fear, weight loss)
• Gradual progression from intermittent to constant pain
• Symptoms triggered by hypotension, dehydration, or decreased cardiac output
• Often more indolent presentation than embolic AMI

NOMI (variable onset in critically ill):

• Difficult clinical recognition in sedated, mechanically ventilated patients
• Abdominal distension (may be only sign in 40-50%)
• Rising lactate despite source control
• Unexplained metabolic acidosis
• Worsening vasopressor requirements
• Feeding intolerance or high gastric residuals
• Occult or frank blood in stool or gastric aspirate

Mesenteric Venous Thrombosis (insidious onset, days to weeks):

• Gradual onset of vague abdominal discomfort
• May have weeks of mild intermittent pain before presentation
• Nausea, anorexia, and malaise
• Lower fever (38-38.5°C) than arterial occlusion
• Sometimes discovered incidentally on imaging for other indications

Physical Examination Findings

Early Phase (first 6-12 hours): The classic finding is pain out of proportion to examination, where the patient writhes in agony but the abdomen is soft with minimal tenderness. This discordance results from visceral pain (intense) without parietal peritoneal involvement (absent early).

• Abdomen: Soft, mild diffuse tenderness, normal or slightly diminished bowel sounds
• Cardiovascular: Tachycardia (90-100% of cases), possibly atrial fibrillation
• General: Diaphoresis, agitation, restlessness

Late Phase (after 12 hours, transmural infarction): Once full-thickness necrosis occurs, parietal peritoneum becomes inflamed, producing classic peritonitis:

• Abdomen: Distended, rigid, rebound tenderness, guarding, absent bowel sounds
• Rectal examination: Occult or frank blood (30-50% of cases)
• Cardiovascular: Tachycardia, hypotension, shock (lactic acidosis, SIRS)
• General: Altered mental status, cool extremities, oliguria

Clinical Scenarios in ICU

Post-Cardiac Surgery: NOMI occurs in 0.5-3% of cardiac surgery patients, typically 2-7 days post-operatively. Risk factors include prolonged cardiopulmonary bypass (\u003e120 minutes), intra-aortic balloon pump use, high-dose vasopressor requirements, and intra-operative hypotension. Presentation is often subtle: rising lactate, base deficit, or unexplained deterioration despite stable cardiac function.

Dialysis Patients: Hemodialysis patients are at 3-4 fold increased risk of AMI, particularly NOMI. Ischemia may occur during or within 24 hours of dialysis due to ultrafiltration-induced hypovolemia and splanchnic vasoconstriction. Symptoms may be attributed to "dialysis intolerance," delaying diagnosis.

Vasopressor-Dependent Patients: Patients requiring noradrenaline \u003e0.3 mcg/kg/min for \u003e24 hours are at high risk for NOMI. Suspect AMI if lactate rises despite source control, vasopressor requirements increase without clear cause, or feeding intolerance develops.

COVID-19 ICU Patients: COVID-19 is associated with increased thrombotic risk affecting both arterial and venous mesenteric vessels. AMI occurred in 1-4% of critically ill COVID-19 patients in early pandemic reports, often with atypical presentations due to concomitant hypercoagulability and endothelial dysfunction.

---

Investigations

Laboratory Markers

Lactate: Serum lactate is the most commonly used biomarker but is neither sensitive nor specific for early AMI. Lactate elevation (\u003e2 mmol/L) has only 86-91% sensitivity and is often a late finding, appearing after transmural ischemia has developed. Lactate \u003e3 mmol/L correlates with bowel necrosis and mortality \u003e50%. Serial lactate measurements are more useful than a single value: rising lactate despite resuscitation strongly suggests progressive bowel ischemia. False negatives occur in up to 25% of patients with early AMI, particularly in embolic cases where lactate may be normal for the first 6-12 hours.

D-dimer: Elevated D-dimer has high sensitivity (95-96%) for AMI but very low specificity (40-50%). A normal D-dimer (\u003c0.5 mg/L) has high negative predictive value (95-99%) and can help exclude AMI in low-risk patients. However, D-dimer is elevated in most ICU patients due to inflammation, infection, surgery, and thrombosis, limiting its utility in critically ill populations. D-dimer is most useful in emergency department evaluation of undifferentiated abdominal pain, where a normal value argues strongly against AMI.

White Blood Cell Count: Leucocytosis (WBC \u003e15 × 10⁹/L) occurs in 75-90% of AMI cases but is non-specific. Severe leucocytosis (\u003e20 × 10⁹/L) suggests bowel necrosis or perforation. A normal WBC does not exclude AMI, particularly in immunosuppressed patients or early presentation.

Metabolic Acidosis: Metabolic acidosis with elevated anion gap develops in 60-80% of patients with established AMI. Base deficit \u003e-6 mmol/L correlates with bowel infarction and poor prognosis. However, compensated acidosis or normal pH does not exclude early ischemia.

Other Markers: Multiple biomarkers have been studied but none have sufficient sensitivity/specificity for routine clinical use:

• Intestinal fatty acid binding protein (I-FABP): Elevated in mucosal ischemia but not widely available
• Alpha-glutathione S-transferase (α-GST): Released from ischemic enterocytes; experimental
• Procalcitonin: Elevated in bowel necrosis with bacterial translocation, but non-specific
• Amylase: Elevated in 25-50% of cases (usually \u003c3× normal)
• Phosphate: Hyperphosphatemia (\u003e1.6 mmol/L) in 30% due to cellular breakdown
• Creatine kinase (CK): Elevated in 50% with bowel infarction

Key Principle: No single laboratory test can reliably diagnose or exclude AMI. Clinical suspicion based on risk factors and presentation should drive imaging, not laboratory results.

Imaging

CT Angiography (Gold Standard): Multidetector CT angiography (MDCTA) has become the first-line diagnostic test for suspected AMI, with pooled sensitivity of 93% and specificity of 96% according to meta-analysis. MDCTA provides simultaneous assessment of mesenteric arterial and venous anatomy, bowel wall perfusion, and presence of complications (perforation, pneumatosis).

Protocol:

• Biphasic acquisition: arterial phase (25-30 second delay) and portal venous phase (65-70 second delay)
• No oral contrast (obscures vascular detail and bowel wall enhancement)
• IV contrast: 100-150 mL at 4-5 mL/sec
• Thin-slice reconstruction (1-2 mm) with multiplanar reformats
• 3D maximum intensity projection (MIP) for vascular imaging

Arterial Findings:

• Embolism: Filling defect within SMA lumen, typically 3-10 cm from origin, "meniscus sign"
• Thrombosis: Occlusion at SMA origin, heavy vascular calcification, collateral vessels
• NOMI: Patent but narrowed ("beaded" or "pruned tree") SMA branches, no occlusion
• Stenosis grading: \u003c50%, 50-70%, 70-99%, or 100% occlusion

Venous Findings (MVT):

• Filling defect or absent opacification of SMV, portal vein, or mesenteric veins
• Bowel wall thickening with "target sign" (enhancing mucosa and serosa, edematous submucosa)
• Mesenteric fat stranding and haziness

Bowel Wall Findings:

• Reduced/absent enhancement: Indicates non-viable bowel (sensitivity 80%, specificity 90%)
• Thickening: \u003e3 mm (non-specific, can occur in edema, inflammation, or ischemia)
• Pneumatosis intestinalis: Gas within bowel wall (82% specificity for transmural necrosis)
• Portal venous gas: Highly specific (95%) for bowel necrosis, indicates bacterial translocation
• Mesenteric fat stranding: Non-specific inflammation or edema

CT Severity Grading: Several grading systems exist; a practical approach:

• Grade I: Arterial occlusion/stenosis, normal bowel wall
• Grade II: Bowel wall thickening or reduced enhancement, no pneumatosis
• Grade III: Pneumatosis intestinalis ± portal venous gas

Plain Abdominal Radiography: Abdominal X-rays are insensitive (30% normal in early AMI) but may show:

• Non-specific ileus (most common finding)
• "Thumbprinting" (submucosal hemorrhage/edema)
• Pneumatosis intestinalis (late finding)
• Portal venous gas (ominous late finding)
• Free intraperitoneal air (perforation)

Plain films are primarily useful to exclude other diagnoses (obstruction, perforation) or in resource-limited settings where CT is unavailable. A normal X-ray does not exclude AMI.

Catheter Angiography (Digital Subtraction Angiography, DSA): Traditional catheter angiography was the historical gold standard but has been largely replaced by CT angiography. Current indications include:

• NOMI diagnosis and treatment (papaverine infusion catheter placement)
• Endovascular intervention (thrombectomy, thrombolysis, angioplasty)
• Equivocal CT findings in high clinical suspicion
• Planning for surgical bypass

Angiographic Findings:

• Embolism: Meniscus sign, filling defect in mid-SMA
• Thrombosis: Flush occlusion at SMA origin, "stump sign"
• NOMI: "String-of-sausages" or "string-of-beads" appearance (alternating vasospasm and normal segments), slow contrast clearance, reduced arterial pulsations
• MVT: Prolonged arterial phase, absent or slow venous filling, "corkscrew" collaterals

Ultrasound (Doppler): Transabdominal ultrasound has limited sensitivity (70-89%) due to bowel gas and operator dependence, but may be useful in selected cases:

• SMA peak systolic velocity \u003c150 cm/sec suggests occlusion or high-grade stenosis
• Absence of flow on color Doppler
• Useful in hemodynamically unstable patients who cannot undergo CT
• Follow-up imaging for MVT response to anticoagulation

MR Angiography: MRA is rarely used in acute AMI due to longer acquisition times, limited availability, and contraindications in critically ill patients (pacemakers, metallic implants, need for continuous monitoring). Sensitivity and specificity are comparable to CTA (92-95%) when performed with gadolinium contrast.

Diagnostic Laparoscopy/Laparotomy: In patients with peritonitis or hemodynamic instability, proceeding directly to surgery without imaging is appropriate. Diagnostic laparoscopy can assess bowel viability in equivocal cases but may underestimate ischemia in early stages and does not allow assessment of retroperitoneal vessels.

Diagnostic Algorithm

High Clinical Suspicion (pain out of proportion, risk factors):

1. Resuscitation (fluids, antibiotics, anticoagulation)
2. Immediate CT angiography (if hemodynamically stable)
3. If unstable or peritonitis → urgent laparotomy
4. If CT equivocal and high suspicion → catheter angiography or laparoscopy

Moderate Clinical Suspicion:

1. Laboratory markers (lactate, D-dimer, WBC)
2. CT angiography
3. If negative and symptoms persist → repeat imaging in 6-12 hours or alternative diagnosis

Low Clinical Suspicion:

1. D-dimer
2. If normal D-dimer → AMI unlikely, consider alternative diagnoses
3. If elevated D-dimer and symptoms persist → CT angiography

---

Management

Initial Resuscitation

Airway and Breathing: Early intubation and mechanical ventilation should be considered in patients with severe metabolic acidosis (pH \u003c7.2), shock, or altered mental status. Positive pressure ventilation may reduce splanchnic blood flow and worsen mesenteric ischemia, so the lowest tolerable PEEP (5-8 cmH₂O) should be used. Target oxygen saturation 94-98% to optimize oxygen delivery without excessive vasoconstriction from hyperoxia.

Circulation: Aggressive intravenous fluid resuscitation is critical to restore intravascular volume and improve mesenteric perfusion. Initial fluid boluses of 20-30 mL/kg of balanced crystalloid (Plasma-Lyte, Hartmann's) should be administered rapidly, targeting mean arterial pressure (MAP) ≥65 mmHg and urine output \u003e0.5 mL/kg/hr. Avoid excessive fluid administration in established bowel necrosis (risk of third-spacing and abdominal compartment syndrome).

Vasopressor Strategy: If hypotension persists despite adequate fluid resuscitation, vasopressor support is required. However, vasopressors can worsen mesenteric ischemia through alpha-adrenergic vasoconstriction:

• First-line: Noradrenaline at lowest effective dose (target MAP 65-70 mmHg, not higher)
• Avoid excessive doses: Noradrenaline \u003e0.3 mcg/kg/min associated with NOMI
• Consider: Adding vasopressin (0.03-0.04 units/min) as noradrenaline-sparing agent
• NOMI patients: Wean vasopressors as rapidly as tolerated; consider inotropic support (dobutamine) to increase cardiac output and splanchnic flow

Hemodynamic Monitoring: Invasive arterial line for continuous blood pressure monitoring and serial blood gas analysis. Central venous catheter for vasopressor administration and CVP monitoring. Consider advanced monitoring (ScvO₂, cardiac output) in shock states to guide resuscitation.

Pharmacological Interventions

Anticoagulation: Systemic anticoagulation with unfractionated heparin (UFH) should be initiated immediately upon diagnosis or strong clinical suspicion, unless active bleeding or recent neurosurgery.

Rationale:

• Prevents propagation of arterial or venous thrombus
• Reduces microvascular thrombosis
• Improves outcomes in all AMI subtypes

Protocol:

• UFH bolus: 80 units/kg IV (maximum 5,000 units)
• Infusion: 18 units/kg/hr (maximum 1,000 units/hr initially)
• Target aPTT: 60-80 seconds (1.5-2.5× control)
• Alternative: Low molecular weight heparin (enoxaparin 1 mg/kg SC q12h) if surgery not imminent

Duration:

• Continue peri-operatively unless contraindicated
• MVT: Lifelong anticoagulation (warfarin, target INR 2-3) after acute phase
• Embolic AMI: Minimum 3-6 months; indefinite if recurrent emboli or persistent AF
• Thrombotic AMI: Indefinite anticoagulation

Contraindications: Absolute contraindications to anticoagulation are rare but include active intracranial bleeding, recent neurosurgery (\u003c7 days), or uncontrolled hemorrhage. Relative contraindications include thrombocytopenia (\u003c50 × 10⁹/L) or recent major surgery, which should be weighed against the high risk of thrombus propagation.

Broad-Spectrum Antibiotics: Empiric antibiotics should be administered within 1 hour of diagnosis to cover gut flora, given the high risk of bacterial translocation:

Regimen:

• First-line: Piperacillin-tazobactam 4.5 g IV q6h OR meropenem 1 g IV q8h
• Penicillin allergy: Ciprofloxacin 400 mg IV q12h PLUS metronidazole 500 mg IV q8h
• Add: Vancomycin 15-20 mg/kg IV q8-12h if risk factors for MRSA or post-operative

Duration:

• Continue until after surgery and reassess based on operative findings
• Bowel resection without perforation: 24-48 hours post-operative
• Perforation or peritonitis: 5-7 days or until clinical improvement

Analgesia: Adequate analgesia is essential but must not mask clinical deterioration:

• Opioids (morphine 2-5 mg IV or fentanyl 25-50 mcg IV) titrated to effect
• Reassess abdomen frequently despite analgesia
• Avoid NSAIDs (worsen mesenteric perfusion and increase bleeding risk)

Nasogastric Decompression: Place nasogastric tube for gastric decompression, particularly if bowel distension, vomiting, or planned surgery. Reduces aspiration risk and improves respiratory mechanics.

Correct Metabolic Derangements:

• Acidosis: Treat underlying cause (resuscitation, source control); consider sodium bicarbonate if pH \u003c7.1 AND acute severe acidosis (controversial, may worsen intracellular acidosis)
• Electrolytes: Correct hypokalemia, hypocalcemia, hypophosphatemia
• Hyperglycemia: Target glucose 6-10 mmol/L with insulin infusion if needed

Subtype-Specific Management

SMA Embolism:

Endovascular-First Strategy (if no peritonitis, stable):

• Catheter-directed thrombolysis: Alteplase 0.5-1 mg/hr via selective SMA catheter for 12-24 hours
• Aspiration thrombectomy: Penumbra or similar devices
• Success rate: 70-85% in patients without peritonitis
• Advantages: Avoids laparotomy, faster recovery
• Complications: Bleeding (10-15%), distal embolization (5-10%)

Surgical Strategy (if peritonitis, hemodynamic instability, or failed endovascular):

• Midline laparotomy
• Assess bowel viability: Color (pink vs dusky), peristalsis, pulsatile mesenteric vessels, Doppler signals
• SMA embolectomy via transverse arteriotomy distal to occlusion
• Fogarty catheter thrombectomy (size 3-4 Fr)
• Resect clearly necrotic bowel; leave questionable segments
• Second-look laparotomy at 24-48 hours to reassess viability

SMA Thrombosis:

Endovascular:

• Angioplasty ± stenting of SMA origin stenosis
• Catheter-directed thrombolysis if acute-on-chronic
• Higher failure rate than embolism (50-60%) due to chronic occlusion

Surgical:

• Supraceliac or infrarenal aorta to SMA bypass (usually saphenous vein or prosthetic graft)
• Antegrade (from supraceliac aorta) or retrograde (from infrarenal aorta or iliac) approach
• Resect non-viable bowel
• May require damage control laparotomy if prolonged ischemia time

Non-Occlusive Mesenteric Ischemia (NOMI):

NOMI management is fundamentally different from occlusive AMI and focuses on reversing vasospasm and optimizing perfusion:

Optimize Hemodynamics:

• Wean vasopressors to minimum effective dose
• Maximize cardiac output: Fluid optimization, inotropes (dobutamine 2.5-10 mcg/kg/min)
• Correct underlying cause: Treat heart failure, arrhythmia, hypovolemia
• Target MAP 65-70 mmHg (not higher; excessive pressures worsen vasospasm)

Intra-arterial Papaverine: If diagnosis confirmed on angiography and no peritonitis:

• Place selective SMA catheter during angiography
• Papaverine bolus: 30-60 mg intra-arterially
• Continuous infusion: 30-60 mg/hour for 24-48 hours
• Monitor for systemic hypotension (papaverine leak into systemic circulation)
• Repeat angiography at 24 hours to assess response
• Success rate: 50-60% if initiated before bowel necrosis; \u003c20% if delayed

Alternative Vasodilators (if papaverine unavailable):

• Prostaglandin E1 (alprostadil): 20-40 ng/kg/min intra-arterially
• Tolazoline: 25 mg bolus, then 10-20 mg/hour
• Glucagon: 0.5-1 mg/hour (less effective, systemic administration)

Surgical:

• Surgery only if peritonitis develops
• Resect necrotic bowel but leave vasodilator catheter in situ
• Mortality 70-90% once laparotomy required

Mesenteric Venous Thrombosis:

Anticoagulation-First Strategy: Most patients with MVT (60-80%) can be managed non-operatively with anticoagulation alone:

• Immediate therapeutic UFH or LMWH
• Transition to warfarin (target INR 2-3) or direct oral anticoagulant (DOAC)
• Duration: 6-12 months if provoked (e.g., pancreatitis); lifelong if unprovoked or thrombophilia
• Success rate: 80-90% with early anticoagulation (before bowel infarction)

Thrombolysis: For extensive thrombus involving SMV and portal vein with clinical deterioration despite anticoagulation:

• Catheter-directed thrombolysis via SMA or transjugular route
• Alteplase 0.5-1 mg/hour for 24-48 hours
• Monitor fibrinogen (risk of systemic lytic state)

Surgical: Indications:

• Peritonitis
• Clinical deterioration despite anticoagulation
• Free intraperitoneal air (perforation)

Procedure:

• Laparotomy, resection of necrotic bowel
• No attempt at venous thrombectomy (technically difficult, not beneficial)
• Continue anticoagulation post-operatively
• Second-look laparotomy in 24-48 hours

Surgical Intervention

Indications for Urgent Laparotomy:

• Peritonitis (rebound tenderness, guarding, rigidity)
• Hemodynamic instability despite resuscitation
• Pneumoperitoneum (free air, perforation)
• Pneumatosis intestinalis or portal venous gas
• Clinical deterioration despite endovascular/medical therapy
• Inability to exclude perforation or other surgical emergency

Pre-operative Preparation:

• Hemodynamic stabilization (fluids, vasopressors)
• Correction of coagulopathy (may require holding heparin, giving FFP/prothrombin complex)
• Antibiotics administered
• Informed consent discussion: High mortality risk, possible stoma, need for second-look surgery

Operative Principles:

Exposure:

• Midline laparotomy (xiphoid to pubis for full exposure)
• Assess for free fluid (blood-tinged or serosanguinous suggests ischemia)
• Systematic inspection of entire bowel from ligament of Treitz to rectum

Assessment of Bowel Viability: Visual inspection alone is unreliable (40% error rate). Use combination of:

• Color: Pink and shiny (viable) vs dusky/purple (questionable) vs black/green (necrotic)
• Peristalsis: Spontaneous or responsive to gentle manipulation
• Mesenteric pulsations: Palpable pulses in arcade vessels
• Doppler ultrasound: Audible arterial signal in bowel wall
• Fluorescence imaging: Indocyanine green (ICG) angiography (if available) shows perfusion in real-time

Revascularization vs Resection: The decision depends on extent of ischemia and likelihood of salvage:

If viable bowel after embolectomy/bypass:

• Complete revascularization first
• Re-examine bowel after 15-20 minutes of reperfusion
• Resect only clearly necrotic segments
• Second-look mandatory to assess delayed necrosis

If extensive necrosis:

• Damage control approach: Resect dead bowel, leave questionable segments
• Do not perform anastomosis at initial surgery
• Leave abdomen open or temporary closure (Bogota bag, VAC dressing)
• ICU resuscitation
• Second-look at 24-48 hours

Embolectomy Technique:

• Expose SMA at base of transverse mesocolon
• Longitudinal arteriotomy distal to palpable embolus
• Fogarty catheter thrombectomy (gentle inflation, slow withdrawal)
• Ensure good inflow and outflow (pulsatile back-bleeding)
• Close arteriotomy with 6-0 Prolene (direct or patch)
• Flush with heparinized saline

Bypass Technique (for SMA thrombosis):

• Supraceliac aorta to SMA bypass (antegrade, shortest conduit)
• OR infrarenal aorta to SMA bypass (retrograde, easier exposure)
• Conduit: Saphenous vein (preferred) or prosthetic (Dacron, PTFE)
• Proximal anastomosis: End-to-side to aorta (6-0 Prolene)
• Distal anastomosis: End-to-side to SMA beyond occlusion

Resection Extent:

• Small bowel: Resect to grossly viable tissue with arterial pulsations
• Ileocecal valve: Preserve if possible (prevents bacterial overgrowth)
• Colon: Resect right colon if involved (Hartmann's procedure or end colostomy)
• Minimum viable small bowel length: 100-150 cm to avoid short bowel syndrome

Stoma vs Anastomosis:

• Primary anastomosis: Only if clearly viable bowel, minimal contamination, hemodynamically stable
• Stoma: If questionable viability, peritoneal contamination, shock, or planned second-look
• End ileostomy or end colostomy preferred over loop stoma (easier to revise)

Second-Look Laparotomy: Mandatory in most cases, planned at 24-48 hours:

• Re-inspect all bowel, especially margins of prior resection
• Resect any further necrosis that has declared itself
• Consider primary anastomosis or definitive stoma if viable
• Multiple second-looks may be needed (10-20% of cases)

Criteria to Avoid Second-Look:

• Clearly viable bowel throughout, complete revascularization
• No questionable segments left in situ
• Hemodynamically stable, lactate normalizing

Post-operative ICU Management

Hemodynamic Management:

• Continued resuscitation: Target MAP 65-70 mmHg, urine output \u003e0.5 mL/kg/hr, ScvO₂ \u003e70%
• Wean vasopressors as tolerated
• Monitor for abdominal compartment syndrome (bladder pressure q4-6h)

Ventilatory Management:

• Lung-protective ventilation: Tidal volume 6-8 mL/kg IBW, plateau pressure \u003c30 cmH₂O
• PEEP 5-10 cmH₂O (balance between oxygenation and avoiding increased intra-abdominal pressure)
• Wean to extubation when resuscitation complete, no further surgeries planned

Anticoagulation:

• Resume UFH 12-24 hours post-operatively if hemostasis adequate
• Continue indefinitely (warfarin transition) based on subtype

Nutrition:

• Keep nil by mouth until bowel function returns and anastomoses/stomas mature
• Parenteral nutrition if prolonged ileus expected (\u003e5-7 days)
• Gradual enteral feeding via nasojejunal tube once bowel sounds return and stoma functioning

Fluid and Electrolyte Management:

• Large third-space losses: Replace with balanced crystalloid
• High stoma output: Replace losses mL for mL with 0.9% saline + KCl
• Monitor for hypomagnesemia, hypophosphatemia (replete aggressively)

Infection Surveillance:

• Continue antibiotics 5-7 days or until clinical improvement
• Monitor for intra-abdominal abscess (fever, leucocytosis, ileus)
• CT abdomen/pelvis if sepsis without clear source

Abdominal Compartment Syndrome (ACS): IAH/ACS occurs in 10-30% of post-operative AMI patients due to bowel edema, third-spacing, and resuscitation:

• Monitor bladder pressure q4-6h
• IAH: Intra-abdominal pressure (IAP) \u003e12 mmHg
• ACS: IAP \u003e20 mmHg with new organ dysfunction
• Management: Nasogastric decompression, rectal tube, minimize fluids, neuromuscular blockade, consider decompressive laparotomy

Multi-Organ Support:

• Acute kidney injury: Common (30-50%), treat with CRRT if needed
• ARDS: From ischemia-reperfusion injury, cytokine release
• Cardiovascular: Myocardial depression, arrhythmias
• Coagulopathy: DIC in 10-20% with bowel necrosis

Monitoring for Complications:

• Anastomotic leak: Fever, abdominal pain, peritonitis, leucocytosis (usually day 5-7)
• Short bowel syndrome: If \u003c150 cm residual small bowel
• Recurrent ischemia: Rising lactate, abdominal pain (urgent CT angiography)

---

Complications

Early Complications (0-7 Days)

Bowel Perforation: Perforation may occur due to missed necrotic segments at initial surgery, progression of ischemia, or anastomotic breakdown. Presents with sudden deterioration, peritonitis, and pneumoperitoneum on imaging. Requires urgent re-laparotomy, resection of perforated segment, washout, and damage control approach. Mortality increases to 80-90% with delayed recognition.

Septic Shock and Multi-Organ Dysfunction: Bowel necrosis leads to bacterial translocation, endotoxemia, and systemic inflammatory response syndrome (SIRS). Up to 60% of patients develop septic shock requiring vasopressor support. MODS occurs in 40-60%, involving lungs (ARDS), kidneys (AKI requiring CRRT in 30-40%), liver (hepatocellular injury), and coagulation (DIC in 10-20%). Mortality exceeds 70% with ≥3 organ failures.

Abdominal Compartment Syndrome: IAH and ACS complicate 10-30% of post-operative AMI cases due to massive fluid resuscitation, bowel edema, and inflammatory exudate. ACS (IAP \u003e20 mmHg with organ dysfunction) causes renal failure, respiratory compromise, decreased cardiac output, and bowel ischemia. Treatment includes medical optimization (decompression, diuresis, neuromuscular blockade) and surgical decompression if refractory.

Anastomotic Leak: Anastomotic dehiscence occurs in 15-25% of patients undergoing primary anastomosis after AMI, due to poor perfusion at resection margins and malnutrition. Typically presents on post-operative day 5-7 with fever, tachycardia, peritonitis, and leucocytosis. CT shows free fluid, extraluminal air, or contrast extravasation. Requires re-laparotomy, resection of anastomosis, and stoma formation.

Bleeding: Post-operative hemorrhage occurs in 10-15%, from coagulopathy (DIC, hypothermia, dilutional), arterial suture lines (embolectomy, bypass), or raw mesenteric surfaces. Presents with hemodynamic instability, falling hemoglobin, and bloody drain output. Requires reversal of anticoagulation, correction of coagulopathy (FFP, platelets, cryoprecipitate), and re-exploration if ongoing bleeding.

Recurrent Ischemia: Recurrent or propagated thrombosis/embolism occurs in 5-10%, especially if anticoagulation interrupted or inadequate. Presents with rising lactate, abdominal pain, and clinical deterioration. Urgent CT angiography and return to OR for thrombectomy/bypass revision.

Intermediate Complications (1-4 Weeks)

Intra-abdominal Abscess: Abscess formation complicates 15-25% of cases, due to contamination at initial surgery, anastomotic leak, or inadequate source control. Presents with persistent fever, leucocytosis, ileus, and failure to wean vasopressors. CT abdomen/pelvis shows fluid collection. Treatment: Percutaneous drainage (if accessible) or surgical drainage, antibiotics for 7-14 days.

Wound Infection and Dehiscence: Surgical site infection occurs in 30-40% due to contamination and malnutrition. Superficial infections respond to opening wound and local care. Fascial dehiscence (burst abdomen) occurs in 5-10%, presents with serosanguinous wound drainage, palpable fascial defect, or evisceration. Requires urgent return to OR for re-closure with retention sutures or mesh.

Short Bowel Syndrome: Extensive small bowel resection (\u003c150 cm remaining) results in short bowel syndrome with malabsorption, diarrhea, and nutritional deficiency. High-output stoma or diarrhea (\u003e2 L/day), dehydration, and electrolyte depletion (hypomagnesemia, hypokalemia) are common. Management includes anti-diarrheal agents (loperamide, codeine), octreotide, parenteral nutrition, and eventual small bowel transplant evaluation if \u003c100 cm remains.

Intestinal Failure: Defined as inability to maintain nutrition/hydration via enteral route. Occurs in 20-30% of survivors, due to short bowel, intestinal fistula, or dysmotility. Requires long-term parenteral nutrition, with risk of line sepsis, thrombosis, and liver disease. Multidisciplinary intestinal failure team essential.

Late Complications (\u003e4 Weeks)

Incisional Hernia: Develops in 30-50% of patients after open abdomen or multiple re-laparotomies. Higher risk with wound infection, malnutrition, and midline incisions. May be asymptomatic or cause pain, bowel obstruction, or strangulation. Elective repair with mesh recommended 6-12 months after index surgery.

Adhesive Small Bowel Obstruction: Occurs in 20-30% within 1-2 years due to extensive adhesions from multiple surgeries and peritoneal inflammation. Presents with abdominal pain, distension, vomiting, and obstipation. CT shows transition point with proximal bowel dilatation. Most resolve with conservative management (bowel rest, NG decompression); surgery if no resolution in 3-5 days or strangulation suspected.

Chronic Mesenteric Ischemia: Survivors with underlying atherosclerotic disease may develop chronic mesenteric ischemia (postprandial pain, food fear, weight loss) if collateral vessels remain stenosed. Requires CT angiography to assess celiac/IMA patency and endovascular or surgical revascularization.

Recurrent Thromboembolism: Patients with embolic source (AF, cardiomyopathy) or thrombophilia remain at risk for recurrent events. Lifelong anticoagulation reduces risk to 2-5% per year. Annual surveillance with clinical assessment and imaging (echocardiography, thrombophilia screening).

Psychological Sequelae: Survivors experience high rates of depression (40-50%), anxiety, and PTSD related to critical illness, multiple surgeries, stoma formation, and chronic disability. Requires psychological support, rehabilitation, and stoma therapy.

---

Prognosis and Outcomes

Mortality

Overall in-hospital mortality for AMI remains 50-70% despite advances in diagnosis and treatment. Mortality varies significantly by subtype, timing of intervention, and presence of bowel infarction:

By Subtype:

• Mesenteric venous thrombosis: 20-30% (lowest; allows time for diagnosis and anticoagulation)
• SMA embolism: 40-60% (moderate; depends on time to revascularization)
• SMA thrombosis: 60-80% (high; often delayed presentation with extensive infarction)
• NOMI: 70-90% (highest; critically ill baseline, difficult diagnosis)

By Timing of Intervention:

• Revascularization \u003c6 hours: 20-30% mortality
• Revascularization 6-12 hours: 50-60% mortality
• Revascularization \u003e12 hours: 70-90% mortality
• Diagnosis after bowel infarction: 80-90% mortality

By Bowel Viability:

• No bowel resection required: 20-30% mortality
• Limited resection (\u003c50 cm): 40-50% mortality
• Extensive resection (\u003e100 cm): 70-80% mortality
• Second-look shows progressive necrosis: 80-90% mortality

Predictors of Mortality

Clinical Factors:

• Age \u003e70 years (OR 2.5)
• Delayed diagnosis (\u003e24 hours from symptom onset, OR 4.2)
• Shock at presentation (OR 3.8)
• Peritonitis at presentation (OR 3.5)
• Multi-organ failure (OR 5.6)

Laboratory Markers:

• Lactate \u003e5 mmol/L (OR 4.1)
• Base deficit \u003e-10 mmol/L (OR 3.2)
• Creatinine \u003e200 μmol/L (OR 2.8)
• Thrombocytopenia \u003c100 × 10⁹/L (OR 2.4)

Imaging Findings:

• Pneumatosis intestinalis (OR 6.5)
• Portal venous gas (OR 8.2)
• Ascites (OR 2.9)
• Bowel wall thickening \u003e5 mm (OR 2.1)

Operative Findings:

• Bowel necrosis requiring resection (OR 5.4)
• Resection length \u003e100 cm (OR 4.8)
• Need for second-look laparotomy (OR 3.7)
• Progressive necrosis at second-look (OR 7.9)

Long-Term Outcomes in Survivors

Quality of Life: Survivors report significantly impaired quality of life due to chronic abdominal pain (40%), diarrhea/malabsorption (50%), stoma (30-40%), and psychological distress (40-50%). At 1 year, only 30-40% of survivors have returned to pre-morbid functional status.

Nutritional Status: Short bowel syndrome affects 20-30% of survivors, requiring long-term parenteral nutrition in 10-15%. Chronic malabsorption, vitamin deficiencies (B12, fat-soluble vitamins), and metabolic bone disease are common. 5-year survival on home parenteral nutrition is 60-70%, with line sepsis and liver failure the major causes of death.

Recurrence: Recurrent mesenteric ischemia occurs in 10-15% of survivors, highest in patients with:

• Inadequate anticoagulation or antiplatelet therapy
• Persistent AF without rate/rhythm control
• Progression of atherosclerotic disease
• Thrombophilia without lifelong anticoagulation

Healthcare Utilization: Survivors have high healthcare costs and utilization: median hospital readmission rate 2-3 per year in first 2 years, primarily for bowel obstruction, dehydration, line sepsis, or recurrent ischemia.

---

Special Populations

Post-Cardiac Surgery Patients

NOMI occurs in 0.5-3% of cardiac surgery patients, with mortality exceeding 80%. Risk factors include prolonged cardiopulmonary bypass (\u003e120 minutes), intra-aortic balloon pump use, vasopressor requirements, and low cardiac output syndrome. Clinical suspicion should be high in patients with rising lactate 2-7 days post-operatively without clear source. CT angiography is diagnostic, but may be delayed due to concerns about contrast nephropathy in patients with AKI. Management focuses on optimizing cardiac output, weaning vasopressors, and early papaverine infusion if NOMI confirmed.

Dialysis-Dependent Patients

Chronic kidney disease and dialysis increase AMI risk 3-4 fold. NOMI is most common, occurring during or within 24 hours of hemodialysis due to ultrafiltration-induced hypovolemia and splanchnic hypoperfusion. Symptoms (abdominal pain, nausea) may be attributed to "dialysis intolerance," delaying diagnosis. Prognosis is particularly poor (mortality 80-90%) due to inability to clear lactate, chronic inflammation, and competing comorbidities. Management includes aggressive resuscitation, hemofiltration rather than intermittent HD, and low threshold for imaging.

COVID-19 ICU Patients

COVID-19 is associated with hypercoagulability and endotheliopathy, increasing risk of both arterial and venous mesenteric thrombosis. AMI occurred in 1-4% of critically ill COVID-19 patients in pandemic reports. Presentation is often atypical due to sedation and prone positioning. D-dimer is universally elevated in severe COVID-19, limiting diagnostic utility. Anticoagulation is recommended (prophylactic or therapeutic based on local protocols), and threshold for CT angiography should be low in patients with abdominal distension, rising lactate, or unexplained deterioration.

Pregnancy

AMI is rare in pregnancy but carries extremely high maternal (50-70%) and fetal (60-80%) mortality. Increased risk in third trimester and postpartum due to hypercoagulability and compression of IMA by gravid uterus. Presentation is often atypical and misdiagnosed as pregnancy-related conditions (preeclampsia, HELLP, placental abruption). CT angiography can be performed with appropriate shielding. Management requires multidisciplinary approach (obstetrics, surgery, ICU) with consideration of cesarean delivery to optimize maternal resuscitation. Fetal monitoring and emergent delivery if viable gestational age.

Elderly and Frail Patients

Age \u003e80 years and frailty independently predict mortality (OR 2.5-3.0). Elderly patients more commonly have comorbid cardiovascular disease, atrial fibrillation, and chronic mesenteric ischemia. Presentation is often delayed due to reduced pain perception or cognitive impairment. Operative risk is higher, and recovery prolonged. Palliative approach should be considered in patients with severe frailty, multiple comorbidities, and extensive bowel necrosis, as outcomes are dismal (mortality \u003e90%) and survivors rarely return to functional baseline.

---

SAQ Practice Questions

SAQ 1: Immediate Management of Suspected AMI

Question: A 72-year-old male presents to the Emergency Department with sudden-onset severe abdominal pain for 4 hours. He has a history of atrial fibrillation (not anticoagulated), ischemic heart disease, and hypertension. On examination, heart rate 110 bpm (irregularly irregular), blood pressure 95/60 mmHg, temperature 37.2°C. Abdomen is soft with mild periumbilical tenderness but no guarding. Bowel sounds are present. Laboratory results: lactate 3.8 mmol/L, WBC 18 × 10⁹/L, Hb 142 g/L, creatinine 110 μmol/L.

Outline your immediate management in the first hour.

---

Model Answer:

This patient has a classic presentation for acute mesenteric ischemia (AMI): sudden severe abdominal pain out of proportion to physical findings, atrial fibrillation as embolic source, and elevated lactate. Immediate management priorities are resuscitation, early diagnosis, and preventing thrombus propagation.

1. Resuscitation and Monitoring (0-15 minutes):

• Large-bore IV access (×2)
• Aggressive fluid resuscitation: 1-2 L balanced crystalloid (Hartmann's, Plasma-Lyte) bolus targeting MAP ≥65 mmHg
• Continuous cardiac monitoring (telemetry for AF monitoring)
• Arterial line placement for continuous BP monitoring and serial blood gas analysis
• Urinary catheter to monitor urine output (target \u003e0.5 mL/kg/hr)
• Supplemental oxygen if hypoxic (target SpO₂ 94-98%)

2. Investigations (0-30 minutes):

• Bloods: Repeat lactate, VBG (base deficit), FBC, U\u0026E, LFT, coagulation profile, Group \u0026 Save
• ECG: Confirm AF, exclude acute MI
• Urgent CT angiography abdomen/pelvis: Biphasic protocol (arterial + venous phase), NO oral contrast
  • Request within 15-30 minutes
  • Do NOT delay for creatinine clearance calculation or hydration protocols given high mortality risk
• Portable CXR: Exclude free air (perforation)

3. Pharmacological Interventions (15-30 minutes):

• Anticoagulation: Unfractionated heparin 80 units/kg IV bolus (max 5,000 units), then 18 units/kg/hr infusion (target aPTT 60-80 seconds). Do NOT wait for imaging confirmation before starting heparin.
• Antibiotics: Broad-spectrum coverage for gut flora:
  • Piperacillin-tazobactam 4.5 g IV OR meropenem 1 g IV
  • "Alternative: Ciprofloxacin 400 mg IV + metronidazole 500 mg IV if beta-lactam allergy"
• Analgesia: Morphine 2-5 mg IV titrated to effect (do NOT withhold for fear of masking examination)
• Antiemetic: Ondansetron 4-8 mg IV if vomiting

4. Nil by Mouth:

• NBM status
• Nasogastric tube placement for gastric decompression (if vomiting or distension)

5. Urgent Surgical and ICU Consultation:

• Alert general/vascular surgery within 15 minutes of presentation
• Alert ICU for potential admission
• If peritonitis develops or patient becomes unstable → proceed directly to OR for laparotomy without waiting for CT

6. Additional Considerations:

• Rate control for AF: If hemodynamically stable, consider metoprolol 2.5-5 mg IV or amiodarone 300 mg IV to optimize cardiac output
• Blood products: Cross-match 4-6 units PRBC in case of operative intervention
• Consent discussion: Early discussion with patient/family about high-risk diagnosis, potential surgery, stoma, second-look procedures, and mortality risk (50-70%)

7. Disposition Based on Imaging:

• If CT shows SMA embolism/thrombosis + no peritonitis: Endovascular intervention (catheter-directed thrombolysis/thrombectomy) OR open surgery (embolectomy/bypass)
• If peritonitis or hemodynamic instability: Immediate laparotomy
• If NOMI: Optimize cardiac output, wean vasopressors, consider intra-arterial papaverine

Key Principles:

• Time is bowel: Mortality \u003c30% if revascularized \u003c6 hours; \u003e80% if \u003e12 hours
• Anticoagulation started immediately on clinical suspicion (prevents thrombus propagation)
• CT angiography is gold standard but do NOT delay if patient deteriorates
• Multidisciplinary approach: ED, surgery, radiology, ICU

---

SAQ 2: Management of NOMI in ICU

Question: A 68-year-old male is day 4 post-coronary artery bypass grafting (CABG). He required intra-aortic balloon pump (IABP) for 48 hours post-operatively and has been on noradrenaline 0.4 mcg/kg/min for persistent low cardiac output. Today, his lactate has risen from 2.1 to 5.8 mmol/L over 6 hours. He is sedated and ventilated. Abdomen is distended with absent bowel sounds. CT angiography shows patent SMA with "pruned tree" appearance of mesenteric branches, bowel wall thickening, but no pneumatosis or free air.

Discuss your management of non-occlusive mesenteric ischemia (NOMI) in this patient.

---

Model Answer:

This patient has classic NOMI in the post-cardiac surgery setting: prolonged cardiopulmonary bypass, IABP use, high-dose vasopressors, and rising lactate with CT findings of mesenteric vasospasm without occlusion. NOMI mortality is 70-90%, requiring aggressive medical management and selective use of invasive therapies.

1. Optimize Cardiac Output and Hemodynamics:

The cornerstone of NOMI management is reversing splanchnic vasoconstriction by improving systemic perfusion:

• Wean vasopressors: Reduce noradrenaline to lowest effective dose (target MAP 65 mmHg, NOT higher)
  • Excessive alpha-agonism worsens mesenteric vasoconstriction
  • Consider adding vasopressin 0.03 units/min as noradrenaline-sparing agent
• Optimize cardiac output:
  • Echocardiography to assess LV function, filling, valves
  • "If low CO: Start inotrope (dobutamine 2.5-10 mcg/kg/min) to increase mesenteric perfusion"
  • "If hypovolemic: Fluid bolus (500 mL crystalloid, reassess)"
  • "If significant MR/AR: Consider valve intervention"
• IABP weaning: Continue IABP if still required for cardiac support; consider discontinuation if cardiac function improving (IABP does not worsen mesenteric ischemia)
• Hemodynamic monitoring: Consider pulmonary artery catheter or minimally invasive CO monitoring (LiDCO, FloTrac) to guide therapy

2. Correct Underlying Causes:

• Treat heart failure aggressively (diuretics, inotropes, mechanical support)
• Correct arrhythmias (AF → cardioversion or rate control)
• Rule out tamponade (bedside echo)
• Optimize preload (CVP 8-12 mmHg)

3. Anticoagulation:

• Continue or start unfractionated heparin (target aPTT 60-80 seconds)
• Prevents microvascular thrombosis
• Liaise with cardiac surgery regarding bleeding risk

4. Antibiotics:

• Continue/start broad-spectrum: Piperacillin-tazobactam 4.5 g IV q6h OR meropenem 1 g IV q8h
• Bacterial translocation likely even without perforation

5. Intra-arterial Papaverine Infusion:

If no peritonitis and patient stable enough for intervention:

• Catheter angiography: Confirm NOMI (string-of-sausages appearance, vasospasm, slow flow)
• Selective SMA catheter placement: Position catheter in proximal SMA
• Papaverine bolus: 30-60 mg intra-arterially
• Continuous infusion: 30-60 mg/hour via catheter left in situ
• Duration: 24-48 hours
• Monitoring:
  • Invasive arterial BP monitoring (risk of systemic hypotension if papaverine leaks)
  • Repeat angiography at 24 hours to assess response
• Contraindications: AV block, severe hypotension
• Complications: Hypotension (most common), catheter-related (thrombosis, dissection, hematoma)

Alternative vasodilators if papaverine unavailable:

• Prostaglandin E1 (alprostadil) 20-40 ng/kg/min intra-arterially
• Tolazoline 25 mg bolus then 10-20 mg/hour
• Nitroglycerin (systemic infusion) 10-100 mcg/min (less effective)

6. Nil by Mouth and Bowel Rest:

• NBM, stop all enteral feeding
• Nasogastric tube on free drainage
• Measure gastric residuals and abdominal girth q4-6h

7. Monitor for Progression to Bowel Necrosis:

Serial assessment for development of surgical indications:

• Clinical: Increasing abdominal distension, new peritonitis (difficult in sedated patient)
• Laboratory: Rising lactate (q4-6h), worsening acidosis, increasing vasopressor requirements
• Imaging: Repeat CT at 12-24 hours if clinical deterioration:
  • Look for pneumatosis intestinalis, portal venous gas, or free air → immediate laparotomy
• Bladder pressure monitoring: q4-6h (risk of abdominal compartment syndrome)

8. Indications for Laparotomy Despite Medical Management:

• Peritonitis (rebound, guarding)
• Pneumoperitoneum (free air)
• Pneumatosis or portal venous gas
• Clinical deterioration despite papaverine (rising lactate, worsening acidosis, increasing vasopressor requirements)

9. Surgical Approach if Laparotomy Required:

• Damage control strategy: Resect clearly necrotic bowel, leave questionable segments
• Leave papaverine catheter in situ to preserve remaining bowel
• Plan second-look laparotomy at 24-48 hours
• Mortality \u003e80% once surgery required for NOMI

10. ICU Supportive Care:

• Sedation: Propofol or midazolam + fentanyl/remifentanil
• Ventilation: Lung-protective strategy (TV 6-8 mL/kg, PEEP 5-8 cmH₂O)
• Renal support: CRRT if AKI/fluid overload (likely given cardiac dysfunction)
• Nutrition: TPN if prolonged NBM anticipated (\u003e5-7 days)

11. Prognostication and Goals of Care Discussion:

• NOMI post-cardiac surgery has 80-90% mortality
• If extensive necrosis at laparotomy → consider palliative approach
• Early family discussion regarding poor prognosis, escalation limits

Key Principles:

• NOMI management is fundamentally different from occlusive AMI (medical not surgical in early phase)
• Focus on reversing vasospasm (wean vasopressors, optimize CO, papaverine)
• Surgery only if peritonitis develops (and carries dismal prognosis)
• Mortality remains 70-90% despite aggressive treatment

---

SAQ 3: CT Angiography Interpretation in AMI

Question: You are the ICU registrar reviewing a CT angiography report for a 75-year-old female with acute abdominal pain, AF, and lactate 4.2 mmol/L. The radiology report states:

"Filling defect in the superior mesenteric artery approximately 4 cm distal to its origin. Segments of small bowel demonstrate reduced enhancement with wall thickening. Mesenteric fat stranding present. No pneumatosis intestinalis. No free intraperitoneal air."

A) What is the most likely diagnosis and pathophysiological subtype? B) Interpret the CT findings in terms of clinical significance. C) What are the management options based on these imaging findings?

---

Model Answer:

A) Diagnosis and Subtype:

Diagnosis: Acute mesenteric ischemia (AMI)

Subtype: Superior mesenteric artery (SMA) embolism

Rationale:

• Filling defect in SMA: Indicates arterial occlusion by thromboembolic material
• Location (4 cm distal to origin): Classic location for emboli, which typically lodge 3-10 cm from SMA origin, beyond the middle colic artery but proximal to jejunal branches
  • This location spares proximal jejunum and transverse colon (supplied proximal to embolus)
  • Causes ischemia to distal jejunum, ileum, and right colon
• Risk factor (atrial fibrillation): 80-90% of SMA emboli originate from left atrial thrombus in AF
• Distinguished from thrombosis: SMA thrombosis occurs at the SMA origin (0-1 cm) in atherosclerotic patients with chronic mesenteric ischemia

B) Interpretation of CT Findings:

Vascular Findings:

• Filling defect in SMA: Direct evidence of arterial occlusion
  • Confirms diagnosis of AMI
  • "Meniscus sign" (concave leading edge of thrombus) is pathognomonic for embolus
  • Location suggests embolism rather than in-situ thrombosis

Bowel Wall Findings:

• Reduced/absent bowel wall enhancement: Most important finding for assessing viability
  • "Normal enhancement: 50-100 Hounsfield units on arterial phase"
  • "Reduced enhancement (\u003c30 HU): Indicates poor perfusion, high risk of necrosis"
  • "Complete absence: Strong predictor of non-viable bowel (80-90% sensitivity, 90% specificity)"
• Bowel wall thickening (\u003e3 mm): Non-specific finding
  • Can indicate edema (early ischemia), hemorrhage (submucosal bleeding), or reperfusion injury
  • Alone does not predict viability

Mesenteric Findings:

• Mesenteric fat stranding: Inflammatory response to ischemia
  • Non-specific (occurs in many abdominal pathologies)
  • Indicates mesenteric edema and inflammation
  • May also see mesenteric haziness or ascites

Absence of Complications:

• No pneumatosis intestinalis: Reassuring
  • Pneumatosis = gas within bowel wall, indicates transmural necrosis with bacterial translocation
  • Specificity 82% for necrosis requiring resection
• No free air: No perforation
  • Allows time for revascularization attempt before surgery
  • If free air present → immediate laparotomy

CT Severity Grade:

• This patient has Grade II AMI:
  • Arterial occlusion + bowel wall changes (reduced enhancement, thickening)
  • No pneumatosis or portal venous gas
  • Indicates high risk of infarction but window for salvage

C) Management Options Based on Imaging:

General Principles:

• Patient has ischemia without evidence of perforation or established transmural necrosis
• Window of opportunity for revascularization (likely \u003c6 hours from symptom onset)
• Two options: Endovascular vs open surgical, depending on institutional resources and patient stability

Option 1: Endovascular-First Strategy (Preferred if Available and No Peritonitis):

Indications:

• No peritonitis on examination
• Hemodynamically stable (or stabilizable with resuscitation)
• Embolus location amenable to catheter access
• Interventional radiology availability

Procedure:

• Catheter angiography via femoral or brachial approach
• Confirm embolus location and extent
• Catheter-directed thrombolysis: Alteplase 0.5-1 mg/hr via selective SMA catheter for 12-24 hours
  • "Success rate: 70-85% in embolic AMI without necrosis"
  • Requires ICU monitoring, serial lactate, clinical exam
• Aspiration thrombectomy: Penumbra or similar devices for mechanical clot retrieval
  • Can be combined with thrombolysis
• Intra-arterial papaverine: 30-60 mg bolus + infusion to reverse vasospasm distal to embolus
• Completion angiography: Confirm restoration of flow

Advantages:

• Avoids laparotomy in 70-80% of patients without necrosis
• Faster recovery, shorter ICU/hospital stay
• Lower morbidity than open surgery

Risks:

• Bleeding (10-15%) from thrombolysis
• Distal embolization (5-10%)
• Delay in surgery if bowel necrosis present or develops

Monitoring:

• ICU admission
• Serial lactate q4-6h (should decrease after successful revascularization)
• Serial abdominal examinations q2-4h (development of peritonitis → laparotomy)
• Repeat CT at 12-24 hours if clinical deterioration

Option 2: Open Surgical Revascularization:

Indications:

• Peritonitis present
• Hemodynamic instability despite resuscitation
• No interventional radiology availability or expertise
• High clinical suspicion of bowel necrosis (lactate \u003e5, severe pain, peritonitis)
• Failed endovascular attempt

Procedure:

• Midline laparotomy
• Assess bowel viability (color, peristalsis, Doppler signals, ICG angiography if available)
• SMA embolectomy:
  • Expose SMA at base of transverse mesocolon
  • Longitudinal arteriotomy distal to embolus
  • Fogarty catheter thrombectomy (size 3-4 Fr)
  • Ensure good inflow/outflow, close arteriotomy with 6-0 Prolene
• Reassess bowel after 15-20 minutes of reperfusion
  • Resect clearly necrotic segments (black, non-peristaltic, no Doppler signal)
  • Leave questionable segments (dusky but some perfusion)
• No primary anastomosis if questionable viability
  • End ileostomy/colostomy or leave ends in discontinuity
• Second-look laparotomy at 24-48 hours to reassess viability

Advantages:

• Immediate assessment and treatment of bowel necrosis
• Definitive revascularization
• No delay if necrosis present

Disadvantages:

• Higher morbidity (wound infection, hernia, longer recovery)
• Requires general anesthesia and laparotomy even if bowel viable

Concurrent Medical Management (Both Options):

• Anticoagulation: UFH 80 units/kg bolus, then 18 units/kg/hr (target aPTT 60-80)
  • Start immediately, continue through intervention
  • May need to hold/reverse briefly for surgery but resume post-op
• Antibiotics: Piperacillin-tazobactam 4.5 g IV q6h OR meropenem 1 g IV q8h
• Resuscitation: Aggressive IV fluids (target MAP ≥65 mmHg, UO \u003e0.5 mL/kg/hr)
• Analgesia: Opioids as needed
• NBM: Nil by mouth, NG tube if vomiting/distension

Decision-Making Framework:

• Stable + no peritonitis → Endovascular first, with low threshold to convert to surgery if:
  • Clinical deterioration (rising lactate, new peritonitis)
  • Failed thrombolysis at 12-24 hours
• Unstable or peritonitis → Immediate surgery

Expected Outcomes:

• If revascularized \u003c6 hours: Mortality 30-40%
• If revascularized 6-12 hours: Mortality 50-60%
• If bowel necrosis present: Mortality 70-80%

Follow-Up:

• Lifelong anticoagulation (warfarin, target INR 2-3, or DOAC) given AF and embolic source
• Rate/rhythm control for AF
• Echocardiography to assess for cardiac thrombus, valve disease
• Consider cardioversion if AF reversible

---

SAQ 4: Second-Look Laparotomy Decision-Making

Question: A 70-year-old male underwent emergency laparotomy 36 hours ago for acute mesenteric ischemia secondary to SMA embolus. At the initial surgery, embolectomy was performed and 80 cm of clearly necrotic ileum was resected. An additional 40 cm of dusky but perfused ileum was left in situ, and the bowel ends were stapled without anastomosis. The abdomen was temporarily closed with a VAC dressing. He is now day 2 post-operatively in ICU, intubated and sedated. Lactate has decreased from 5.6 to 2.8 mmol/L. Noradrenaline 0.15 mcg/kg/min. Stoma output is 200 mL of green fluid over 24 hours.

Discuss your approach to the planned second-look laparotomy, including timing, assessment techniques, and possible operative scenarios.

---

Model Answer:

This case illustrates the critical role of second-look laparotomy in AMI management. The patient underwent damage control surgery with resection of necrotic bowel but left questionable segments in situ, which is standard practice when viability is uncertain. Second-look allows reassessment after resuscitation and reperfusion.

1. Indications and Rationale for Second-Look Laparotomy:

Why Second-Look is Mandatory:

• Ischemia-reperfusion injury: Bowel that appeared viable at initial surgery may become necrotic over 24-48 hours due to reperfusion injury, microvascular thrombosis, or inadequate revascularization
• Progression of ischemia: Residual thrombus, vasospasm, or low-flow states can cause progression
• Accuracy of visual assessment: Intra-operative visual assessment alone has 40% error rate in predicting viability
• Avoidance of anastomosis: No primary anastomosis was performed due to uncertainty, necessitating second-look for definitive management

When Second-Look is NOT Needed:

• All bowel clearly viable at initial surgery
• Complete revascularization achieved
• Primary anastomosis performed safely
• Hemodynamically stable with normalizing lactate

2. Timing of Second-Look:

Optimal Timing: 24-48 Hours After Initial Surgery

This patient is at 36 hours, which is appropriate.

Rationale for 24-48 Hour Window:

• Too early (\u003c24 hours): Ischemia-reperfusion injury still evolving; bowel may appear better than it is; risk of premature anastomosis
• Too late (\u003e48-72 hours): Risk of perforation of questionable bowel left in situ; anastomotic complications if delayed
• Current evidence: 36-48 hours is optimal for accurate reassessment

Modify Timing Based on Clinical Status:

Bring forward (\u003c24 hours) if:

• Clinical deterioration (rising lactate, increasing vasopressors, new fever)
• Hemodynamic instability
• Suspected perforation (pneumoperitoneum on CXR, peritoneal drain with feculent/enteric output)

Delay (\u003e48 hours) if:

• Severe coagulopathy (DIC, hypothermia)
• Hemodynamic instability preventing safe anesthesia
• Multi-organ failure requiring optimization
• (Rare; generally proceed at 48 hours regardless)

This patient: Stable trajectory (lactate 5.6 → 2.8, low-dose vasopressor, stoma functioning). Proceed with second-look at 36-48 hours as planned.

3. Pre-Operative Preparation:

Hemodynamic Optimization:

• Continue resuscitation: Target MAP ≥65 mmHg, UO \u003e0.5 mL/kg/hr, lactate \u003c2 mmol/L
• Wean vasopressors if possible (noradrenaline 0.15 mcg/kg/min is acceptable)
• Optimize cardiac output (echocardiography, consider inotropes if low CO)

Correct Coagulopathy:

• Check INR, aPTT, fibrinogen, platelets
• May need to hold heparin for 4-6 hours pre-op (restart post-op)
• Transfuse if needed: Platelets if \u003c50 × 10⁹/L, FFP if INR \u003e1.8, cryoprecipitate if fibrinogen \u003c1.5 g/L

Antibiotics:

• Continue broad-spectrum coverage (piperacillin-tazobactam or meropenem)

Consent:

• Discuss with family: Possible scenarios (bowel viable, further resection, short bowel syndrome, stoma formation, poor prognosis if extensive further necrosis)

4. Intra-Operative Assessment Techniques:

Systematic Bowel Examination:

• Run entire bowel from ligament of Treitz to rectum
• Identify previously resected segments and margins
• Focus on the 40 cm of "questionable" ileum left at initial surgery

Visual Inspection:

• Color:
  • Pink, shiny serosa → Viable
  • Dusky purple → Questionable
  • Black, green, or gray → Necrotic
• Peristalsis:
  • Spontaneous or responsive to gentle manipulation → Viable
  • Absent → Non-viable
• Serosal appearance:
  • Shiny → Viable
  • Dull, fibrinous exudate → Questionable/necrotic
• Mesenteric pulsations:
  • Palpable arcade vessels → Viable
  • Absent pulses → Ischemic

Adjunctive Techniques:

Doppler Ultrasound (Bedside):

• Handheld Doppler on anti-mesenteric bowel wall
• Audible arterial signal → Viable
• Weak or absent signal → Non-viable
• Sensitivity 90%, specificity 85%

Indocyanine Green (ICG) Fluorescence Angiography (Gold Standard if Available):

• Inject ICG 0.2-0.3 mg/kg IV
• Assess bowel perfusion under near-infrared camera
• Fluorescence indicates perfusion; absence indicates non-viable
• Sensitivity 95%, specificity 92%
• Allows precise determination of resection margins (ensure fluorescence at cut edge)

Wood's Lamp (Fluorescein):

• Alternative to ICG if not available
• Inject fluorescein 10-15 mg/kg IV
• Assess under ultraviolet (Wood's) lamp
• Green fluorescence → Viable

Clinical Assessment (Surgeon's Judgment):

• Experienced surgeon assessment remains important
• Combine visual, tactile, and adjunctive findings

5. Possible Operative Scenarios and Management:

Scenario A: All Bowel Viable (Best Case, 30-40% of Second-Looks)

Findings:

• 40 cm of previously questionable ileum now pink, peristaltic, pulsatile mesenteric vessels, Doppler signals present

Management:

• Primary anastomosis between proximal and distal bowel ends
• Consider end-to-end hand-sewn anastomosis (2-layer or single-layer) vs stapled anastomosis
• Test anastomosis for leak (air insufflation via NG tube with bowel clamped distal to anastomosis, submerge in saline)
• Close abdomen primarily (if no excessive tension; otherwise delayed closure or VAC)
• Patient can potentially start enteral feeding in 3-5 days once ileus resolves

Prognosis:

• Good; mortality 30-40%
• Length of residual small bowel = Total SB (typically 300-400 cm) - 80 cm resected initially = 220-320 cm remaining
• No short bowel syndrome risk (need \u003e150 cm to avoid)

Scenario B: Limited Further Necrosis (Moderate, 30-40% of Second-Looks)

Findings:

• Proximal 25 cm of questionable ileum viable
• Distal 15 cm necrotic (black, no perfusion, no Doppler)
• Clear demarcation between viable and non-viable

Management:

• Resect additional 15 cm of necrotic ileum
• Ensure margins are viable (pink, bleeding, Doppler signal, ICG fluorescent)
• Primary anastomosis between viable ends
• OR create end ileostomy if concern about anastomotic viability
• Close abdomen

Prognosis:

• Moderate; mortality 50-60%
• Total resection: 80 + 15 = 95 cm
• Remaining small bowel: 205-305 cm (still adequate, no short bowel)

Scenario C: Extensive Further Necrosis (Poor, 20-30% of Second-Looks)

Findings:

• All 40 cm of questionable ileum necrotic
• Additional proximal or distal extension of necrosis
• Total bowel requiring resection \u003e150-200 cm

Management:

• Further resection: Resect all necrotic bowel to viable margins
• Assess total remaining length:
  • "If \u003e150 cm remains: Proceed with anastomosis or stoma"
  • "If \u003c150 cm remains: Short bowel syndrome likely"
  • "If \u003c100 cm remains: Intestinal failure, parenteral nutrition-dependent"
• Damage control if unstable: Resect dead bowel, staple ends, leave open, plan third-look in 24-48 hours
• Consider goals of care discussion: If \u003c50 cm viable bowel, prognosis dismal (mortality \u003e90%, lifelong TPN if survives, high risk of TPN complications)

Prognosis:

• Poor; mortality 80-90%
• Short bowel syndrome
• Long-term parenteral nutrition
• Consider small bowel transplant evaluation if \u003c100 cm

Scenario D: No Viable Bowel (Worst, \u003c5% but Universally Fatal)

Findings:

• Entire small bowel from ligament of Treitz to ileocecal valve necrotic
• No viable bowel to anastomose

Management:

• Palliative approach: Abort surgery, withdraw care
• Resection would leave no functional small bowel
• Not compatible with life
• Compassionate discussion with family

6. Post-Second-Look ICU Management:

If Viable Bowel/Anastomosis Performed:

• Continue antibiotics 24-48 hours (total 5-7 days if perforation/contamination)
• Resume heparin anticoagulation (12-24 hours post-op if hemostasis adequate)
• Gradual wean from ventilator and vasopressors
• NBM for 3-5 days until ileus resolves, then gradual enteral feeding
• Transition to lifelong anticoagulation (warfarin, target INR 2-3) for embolic source

If Further Necrosis/Unstable:

• Continued critical care support
• Third-look laparotomy in 24-48 hours if questionable segments left
• Parenteral nutrition if prolonged NBM anticipated
• Monitor for complications: anastomotic leak (day 5-7), abscess, ACS

7. Key Principles of Second-Look Laparotomy:

• Mandatory in most AMI cases (unless clearly viable bowel at initial surgery)
• Timing 24-48 hours (earlier if deterioration, not later than 72 hours)
• Use adjuncts (Doppler, ICG) to improve accuracy of viability assessment
• Resect to viable margins (confirmed by perfusion assessment)
• Consider anastomosis only if clearly viable bowel with good perfusion
• Plan third-look if any questionable segments remain
• Short bowel threshold: \u003c150 cm at risk, \u003c100 cm intestinal failure
• Goals of care: If \u003c50 cm viable, consider palliative approach

This Patient's Likely Scenario: Given improving lactate (5.6 → 2.8), low vasopressor requirement, and functioning stoma, likely Scenario A (viable bowel) or B (limited necrosis). Proceed with second-look at 36-48 hours, assess with ICG if available, perform anastomosis if viable, close abdomen, wean support, discharge to ward in 3-5 days.

---

Viva Voce Scenarios

Viva 1: Diagnostic Approach to Acute Mesenteric Ischemia

Examiner Stem: You are the ICU consultant. The emergency department calls about a 78-year-old female with sudden-onset severe abdominal pain for 3 hours. She has atrial fibrillation and hypertension. Her observations: HR 115 bpm (irregularly irregular), BP 100/65 mmHg, RR 24/min, SpO₂ 96% on room air. Abdominal examination shows mild periumbilical tenderness but the abdomen is soft with normal bowel sounds. Lactate is 3.2 mmol/L.

Question 1: What is your differential diagnosis, and what is the most likely diagnosis?

Expected Answer:

• Differential diagnosis for acute severe abdominal pain in elderly patient with AF:

  1. Acute mesenteric ischemia (embolic or thrombotic) – Most likely given sudden onset, AF as embolic source, pain out of proportion
  2. Ruptured abdominal aortic aneurysm
  3. Perforated viscus (peptic ulcer, diverticulitis)
  4. Acute pancreatitis
  5. Bowel obstruction
  6. Ischemic colitis (usually less severe)

• Most likely: Acute mesenteric ischemia (SMA embolism)

  • "Classic triad: Sudden severe pain + out of proportion to exam + high-risk patient (AF)"
  • AF is embolic source in 80% of embolic AMI
  • Lactate elevation (though 3.2 is mild, it will rise)
  • "Time course: 3 hours is consistent with embolic event"

Examiner: Good. What is the pathophysiological mechanism of AMI in this patient?

Expected Answer:

• Embolic occlusion of superior mesenteric artery (SMA):

  • Left atrial thrombus (from AF) embolizes to SMA
  • Emboli typically lodge 3-10 cm distal to SMA origin (beyond middle colic artery)
  • Causes acute occlusion of SMA, cutting off blood supply to midgut (jejunum, ileum, proximal colon)
  • No time for collateral development → rapid progression to ischemia

• Ischemic cascade:

  • "0-3 hours: Mucosal ischemia (villous tip necrosis) – pain present but lactate may be normal"
  • "3-6 hours: Transmural ischemia – sloughing of mucosa, bloody diarrhea, lactate rises"
  • "6-12 hours: Full-thickness necrosis – peritonitis, shock, lactic acidosis"
  • "\u003e12 hours: Gangrene, perforation, multi-organ failure"

• Time is bowel: Mortality \u003c30% if revascularized \u003c6 hours; \u003e80% if \u003e12 hours

Examiner: What investigations would you request and in what order of priority?

Expected Answer:

Immediate (within 15-30 minutes):

1. CT angiography abdomen/pelvis (GOLD STANDARD)

   • Biphasic protocol (arterial + portal venous phase)
   • NO oral contrast (obscures bowel wall enhancement)
   • Sensitivity 93%, specificity 96%
   • Shows: SMA occlusion site, bowel wall perfusion, complications (pneumatosis, perforation)
   • Do NOT delay for creatinine or hydration – mortality risk \u003e\u003e AKI risk

2. Bloods:

   • Repeat lactate (serial q2-4h)
   • VBG (base deficit, pH)
   • FBC (WBC), U\u0026E, coagulation, Group \u0026 Save

3. ECG: Confirm AF, exclude MI

4. Portable CXR: Exclude free air (perforation)

Do NOT Wait For:

• Lactate to normalize (will worsen)
• Further clinical deterioration (too late)
• "Observation period" (delays definitive management)

Other Tests (Lower Priority):

• D-dimer: High sensitivity (95%) but low specificity; normal D-dimer can help exclude AMI in low-risk patients, but this patient is high-risk
• Plain abdominal X-ray: Insensitive (30% normal in early AMI); may show ileus or late signs (pneumatosis, portal venous gas)

Examiner: The CT angiography shows a filling defect in the SMA 5 cm from its origin. The small bowel shows reduced enhancement but no pneumatosis or free air. What are your management priorities?

Expected Answer:

Immediate Management (First Hour):

1. Resuscitation:

   • Large-bore IV access (×2)
   • Aggressive fluid resuscitation: 1-2 L crystalloid bolus (target MAP ≥65 mmHg)
   • Arterial line for continuous BP monitoring
   • Urinary catheter (monitor UO)

2. Anticoagulation (START IMMEDIATELY):

   • Unfractionated heparin 80 units/kg IV bolus, then 18 units/kg/hr infusion
   • Target aPTT 60-80 seconds
   • Prevents thrombus propagation
   • Do NOT wait for surgical review

3. Antibiotics:

   • Broad-spectrum: Piperacillin-tazobactam 4.5 g IV OR meropenem 1 g IV
   • Covers gut flora (E. coli, anaerobes)

4. NBM:

   • Nil by mouth
   • NG tube if vomiting/distension

5. Analgesia:

   • Opioids (morphine, fentanyl) – do NOT withhold

Definitive Management (Revascularization):

Two options: Endovascular vs Open Surgery

Endovascular-First (Preferred if no peritonitis, stable):

• Catheter angiography + catheter-directed thrombolysis (alteplase 0.5-1 mg/hr for 12-24h)
• OR aspiration thrombectomy
• Success rate 70-85% in embolic AMI without necrosis
• Avoids laparotomy

Open Surgery (if peritonitis, unstable, or no IR available):

• Laparotomy, SMA embolectomy (Fogarty catheter)
• Resect necrotic bowel
• Second-look at 24-48 hours

This patient: No peritonitis, hemodynamically stable → Endovascular first

• ICU admission
• Urgent IR consultation
• Catheter-directed thrombolysis
• Serial lactate, clinical exam (watch for peritonitis → convert to surgery)

Examiner: What would make you proceed directly to surgery instead of endovascular?

Expected Answer:

Absolute Indications for Immediate Laparotomy:

1. Peritonitis (rebound, guarding, rigidity)
2. Hemodynamic instability despite resuscitation (shock)
3. Free intraperitoneal air (perforation)
4. Pneumatosis intestinalis or portal venous gas (transmural necrosis)

Relative Indications:

• High suspicion of bowel necrosis (lactate \u003e5, severe metabolic acidosis)
• No interventional radiology availability/expertise
• Delay to endovascular suite \u003e2-3 hours
• Equivocal imaging but high clinical suspicion

This patient: None of these apply → Endovascular appropriate

---

Viva 2: Management of NOMI in Post-Cardiac Surgery Patient

Examiner Stem: You are the ICU consultant. It is day 5 post-coronary artery bypass grafting (CABG) on a 70-year-old male. He had a complicated post-operative course requiring intra-aortic balloon pump (IABP) for 48 hours and has been on noradrenaline 0.3-0.4 mcg/kg/min for persistent low cardiac output. His lactate has risen from 1.8 to 4.5 mmol/L over the last 12 hours. He is sedated and ventilated. On examination, his abdomen is distended with absent bowel sounds. You request a CT angiography which shows: "Patent SMA with narrowed, beaded appearance of mesenteric branches. Bowel wall thickening. No occlusion, pneumatosis, or free air."

Question 1: What is the diagnosis, and what is the underlying pathophysiology?

Expected Answer:

Diagnosis: Non-occlusive mesenteric ischemia (NOMI)

Pathophysiology:

Mechanism:

• NOMI results from intense mesenteric vasoconstriction in the absence of anatomic vessel occlusion
• Occurs in critically ill patients with:
  1. Low cardiac output (post-CABG, heart failure, cardiogenic shock)
  2. Vasopressor therapy (alpha-adrenergic vasoconstrictors like noradrenaline)
  3. Systemic hypoperfusion (hypovolemia, sepsis)

Vicious Cycle:

1. Low cardiac output → Compensatory splanchnic vasoconstriction (divert blood to brain/heart)
2. Exogenous vasopressors (noradrenaline) → Further mesenteric vasoconstriction (alpha-1 receptors)
3. Mesenteric ischemia → Local release of vasoconstrictors (endothelin, thromboxane)
4. Sustained vasospasm persists even after cardiac output improves
5. Prolonged ischemia → Mucosal injury → Bacterial translocation → Shock → More vasopressors → Vicious cycle

CT Findings:

• "Narrowed, beaded appearance" = Vasospasm of mesenteric arterioles
• Also described as "pruned tree" or "string-of-sausages"
• Patent SMA excludes embolism/thrombosis
• Bowel wall thickening = Edema/ischemia

Risk Factors in This Patient:

• Post-cardiac surgery (0.5-3% incidence of NOMI)
• IABP use
• High-dose vasopressors (noradrenaline \u003e0.3 mcg/kg/min for \u003e24 hours)
• Prolonged low cardiac output

Examiner: How is NOMI management different from embolic mesenteric ischemia?

Expected Answer:

Fundamental Difference: Medical vs Surgical

Embolic/Thrombotic AMI:

• Anatomic occlusion → Requires revascularization (endovascular or surgical embolectomy)
• Surgery/intervention is primary treatment

NOMI:

• Functional vasoconstriction (no anatomic occlusion) → Requires reversal of vasospasm
• Medical management is primary treatment
• Surgery only if peritonitis (and prognosis dismal if requires surgery)

NOMI-Specific Management:

1. Optimize Hemodynamics (Reverse Vasospasm):

• Wean vasopressors: Reduce noradrenaline to MINIMUM effective dose (target MAP 65 mmHg, NOT higher)
  • Consider vasopressin (0.03 units/min) as noradrenaline-sparing
• Increase cardiac output:
  • Inotropes (dobutamine 2.5-10 mcg/kg/min) to increase mesenteric flow
  • Optimize preload (fluids, echo-guided)
  • Treat heart failure (diuretics if overloaded)
  • Correct arrhythmias (rate/rhythm control)
• Rule out tamponade (bedside echo)

2. Intra-arterial Papaverine (Definitive for NOMI):

• Indication: Confirmed NOMI on angiography, no peritonitis
• Mechanism: Phosphodiesterase inhibitor → Smooth muscle relaxation → Reverses vasospasm
• Procedure:
  • Catheter angiography (confirm vasospasm)
  • Selective SMA catheter placement
  • Papaverine bolus 30-60 mg intra-arterially
  • Continuous infusion 30-60 mg/hour for 24-48 hours
  • Repeat angiography at 24h to assess response
• Success rate: 50-60% if started before bowel necrosis; \u003c20% if delayed
• Monitoring: Risk of systemic hypotension (papaverine leak)
• Alternatives: Prostaglandin E1, tolazoline (if papaverine unavailable)

3. Antibiotics:

• Broad-spectrum (piperacillin-tazobactam or meropenem)
• Bacterial translocation likely

4. Anticoagulation:

• UFH (prevents microvascular thrombosis)
• May be contraindicated post-cardiac surgery (bleeding risk) – individualize

5. NBM:

• Nil by mouth
• NG tube on free drainage
• Bowel rest

6. Serial Monitoring for Progression:

• Clinical: Abdominal exam q2-4h (difficult in sedated patient)
• Laboratory: Lactate q4-6h (should decrease if treatment effective)
• Imaging: Repeat CT if deterioration (watch for pneumatosis, portal venous gas, free air)
• Bladder pressure: q4-6h (risk of abdominal compartment syndrome)

7. Surgery ONLY If:

• Peritonitis develops
• Pneumatosis/portal venous gas/free air
• Clinical deterioration despite papaverine (rising lactate, worsening acidosis)
• Prognosis if surgery needed: 70-90% mortality

Key Principles:

• NOMI is a medical disease (not surgical initially)
• Wean vasopressors, optimize CO, papaverine are mainstays
• Surgery is a failure of medical management and has dismal prognosis

Examiner: The patient's lactate continues to rise to 7.2 mmol/L despite papaverine infusion. On examination, the abdomen is now rigid with absent bowel sounds. What do you do?

Expected Answer:

Diagnosis: Clinical peritonitis suggesting bowel necrosis despite papaverine therapy.

Management: Urgent laparotomy

Indications for Surgery in NOMI:

• Peritonitis (rebound, guarding, rigidity) – Present in this patient
• Rising lactate despite treatment (4.5 → 7.2) – Present
• Pneumoperitoneum (free air, perforation)
• Pneumatosis or portal venous gas (if on repeat CT)

Pre-operative:

• Inform surgeons urgently
• Continue resuscitation (fluids, vasopressors)
• Correct coagulopathy (common post-CABG): FFP, platelets, consider holding heparin
• Antibiotics already running
• Consent discussion with family: Poor prognosis (mortality 80-90% once surgery needed for NOMI)

Operative Approach (Damage Control):

• Midline laparotomy
• Assess bowel viability (color, peristalsis, Doppler, ICG if available)
• Resect clearly necrotic bowel to viable margins
• Leave questionable segments (do NOT extend resection unless clearly dead)
• NO primary anastomosis (viability uncertain, patient unstable)
• Leave papaverine catheter in situ (continue infusion to preserve remaining bowel)
• Temporary abdominal closure (VAC, Bogota bag)
• Second-look laparotomy at 24-48 hours

Post-operative ICU:

• Continued critical care support
• Wean vasopressors as tolerated
• Continue papaverine infusion (perfuse remaining bowel)
• Plan second-look
• Monitor for complications (ACS, MODS)

Prognostication:

• Mortality 80-90% once laparotomy required for NOMI
• Short bowel syndrome likely if extensive resection
• Consider goals of care discussion if \u003c100 cm viable bowel

Key Message:

• NOMI requiring surgery has dismal prognosis
• Surgery is damage control (resect dead, preserve questionable, second-look)
• Continue papaverine despite surgery (salvage remaining bowel)

---

References

1. Bala M, Kashuk J, Moore EE, et al. Acute mesenteric ischemia: updated guidelines of the World Society of Emergency Surgery. World J Emerg Surg. 2022;17(1):54. PMID: 35918733. doi:10.1186/s13017-022-00443-x

2. Björck M, Koelemay M, Acosta S, et al. Editor's Choice - Management of the Diseases of Mesenteric Arteries and Veins: Clinical Practice Guidelines of the European Society of Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2017;53(4):460-510. PMID: 28838844. doi:10.1016/j.ejvs.2017.01.010

3. Menke J. Diagnostic performance of multidetector CT angiography in acute mesenteric ischemia: systematic review and meta-analysis. Radiology. 2010;256(1):93-101. PMID: 20574087. doi:10.1148/radiol.10091938

4. Oldenburg WA, Lau LL, Rodenberg TJ, et al. Acute mesenteric ischemia: a clinical review. Arch Intern Med. 2004;164(10):1054-1062. PMID: 15159262. doi:10.1001/archinte.164.10.1054

5. Acosta S. Epidemiology of mesenteric vascular disease: clinical implications. Semin Vasc Surg. 2010;23(1):4-8. PMID: 20298945. doi:10.1053/j.semvascsurg.2009.12.001

6. Tilsed JV, Casamassima A, Kurihara H, et al. ESTES guidelines: acute mesenteric ischaemia. Eur J Trauma Emerg Surg. 2016;42(2):253-270. PMID: 26883257. doi:10.1007/s00068-016-0634-0

7. Trompeter M, Brazda T, Remy CT, et al. Non-occlusive mesenteric ischemia: etiology, diagnosis, and interventional therapy. Eur Radiol. 2002;12(5):1179-1187. PMID: 11976865. doi:10.1007/s00330-001-1220-2

8. Kozuch PL, Brandt LJ. Review article: diagnosis and management of mesenteric ischaemia with an emphasis on pharmacotherapy. Aliment Pharmacol Ther. 2005;21(3):201-215. PMID: 15691294. doi:10.1111/j.1365-2036.2005.02269.x

9. Wyers MC. Acute mesenteric ischemia: diagnostic approach and surgical treatment. Semin Vasc Surg. 2010;23(1):9-20. PMID: 20298946. doi:10.1053/j.semvascsurg.2009.12.002

10. Cudnik MT, Darbha S, Jones J, et al. The diagnosis of acute mesenteric ischemia: A systematic review and meta-analysis. Acad Emerg Med. 2013;20(11):1087-1100. PMID: 24238311. doi:10.1111/acem.12254

11. Bourcier S, Ulmann G, Jamme M, et al. A multicentric prospective observational study of diagnosis and prognosis features in ICU mesenteric ischemia: the DIAGOMI study. Ann Intensive Care. 2022;12(1):113. PMID: 36472721. doi:10.1186/s13613-022-01084-1

12. Kärkkäinen JM, Lehtimäki TT, Manninen H, Paajanen H. Acute Mesenteric Ischemia Is a More Common Cause than Expected of Acute Abdomen in the Elderly. J Gastrointest Surg. 2015;19(8):1407-1414. PMID: 26001369. doi:10.1007/s11605-015-2830-3

13. Klar E, Rahmanian PB, Bücker A, et al. Acute mesenteric ischemia: a vascular emergency. Dtsch Arztebl Int. 2012;109(14):249-256. PMID: 22532815. doi:10.3238/arztebl.2012.0249

14. Kärkkäinen JM, Acosta S. Acute mesenteric ischemia (Part I) - Incidence, etiologies, and how to improve early diagnosis. Best Pract Res Clin Gastroenterol. 2017;31(1):15-25. PMID: 28395782. doi:10.1016/j.bpg.2016.10.018

15. Acosta S, Kärkkäinen JM. Acute mesenteric ischemia (Part II) - Vascular and endovascular surgical approaches. Best Pract Res Clin Gastroenterol. 2017;31(1):27-33. PMID: 28395783. doi:10.1016/j.bpg.2016.10.006

16. Block T, Nilsson TK, Björck M, Acosta S. Diagnostic accuracy of plasma biomarkers for intestinal ischaemia. Scand J Clin Lab Invest. 2008;68(3):242-248. PMID: 18609093. doi:10.1080/00365510701646264

17. Emile SH. Predictive factors for intestinal transmural necrosis in patients with acute mesenteric ischemia. World J Surg. 2018;42(8):2364-2372. PMID: 29411078. doi:10.1007/s00268-018-4503-7

18. Beaulieu RJ, Arnaoutakis KD, Abularrage CJ, et al. Comparison of open and endovascular treatment of acute mesenteric ischemia. J Vasc Surg. 2014;59(1):159-164. PMID: 24139984. doi:10.1016/j.jvs.2013.06.084

19. Schermerhorn ML, Giles KA, Hamdan AD, et al. Mesenteric revascularization: management and outcomes in the United States, 1988-2006. J Vasc Surg. 2009;50(2):341-348.e1. PMID: 19372025. doi:10.1016/j.jvs.2009.03.004

20. Arthurs ZM, Titus J, Bannazadeh M, et al. A comparison of endovascular revascularization with traditional therapy for the treatment of acute mesenteric ischemia. J Vasc Surg. 2011;53(3):698-704. PMID: 21236616. doi:10.1016/j.jvs.2010.09.049

21. Ryer EJ, Kalra M, Oderich GS, et al. Revascularization for acute mesenteric ischemia. J Vasc Surg. 2012;55(6):1682-1689. PMID: 22277690. doi:10.1016/j.jvs.2011.12.017

22. Reck T, Jäger K, Düx M, et al. [Ischemia of the intestine and colon--relevance and therapy concepts]. Chirurg. 2001;72(12):1428-1442. German. PMID: 11824031. doi:10.1007/s001040170007

23. Kassahun WT, Fangmann J, Harms J, et al. Intestinal ischaemia: analysis of a German hospital discharge data from 2005-2014. BMC Surg. 2019;19(1):42. PMID: 30943964. doi:10.1186/s12893-019-0508-x

24. Luther B, Mamopoulos A, Lehmann C, Klar E. The Ongoing Challenge of Acute Mesenteric Ischemia. Visc Med. 2018;34(3):215-221. PMID: 30140696. doi:10.1159/000490318

25. Adaba F, Askari A, Dastur J, et al. Mortality after acute primary mesenteric infarction: a systematic review and meta-analysis of observational studies. Colorectal Dis. 2015;17(7):566-577. PMID: 25523777. doi:10.1111/codi.12868

26. Cosse C, Sabbagh C, Kamel S, et al. Procalcitonin and intestinal ischemia: a review of the literature. World J Gastroenterol. 2014;20(47):17773-17778. PMID: 25548477. doi:10.3748/wjg.v20.i47.17773

27. Powell A, Armstrong P. Plasma biomarkers for early diagnosis of acute intestinal ischemia. Semin Vasc Surg. 2014;27(3-4):170-175. PMID: 26073829. doi:10.1053/j.semvascsurg.2015.01.008

28. van den Heijkant TC, Aerts BA, Teijink JA, et al. Challenges in diagnosing mesenteric ischemia. World J Gastroenterol. 2013;19(9):1338-1341. PMID: 23538536. doi:10.3748/wjg.v19.i9.1338

29. Demir IE, Ceyhan GO, Friess H. Beyond lactate: is there a role for serum lactate measurement in diagnosing acute mesenteric ischemia? Dig Surg. 2012;29(3):226-235. PMID: 22699523. doi:10.1159/000338886

30. Evennett NJ, Petrov MS, Mittal A, Windsor JA. Systematic review and pooled estimates for the diagnostic accuracy of serological markers for intestinal ischemia. World J Surg. 2009;33(7):1374-1383. PMID: 19424744. doi:10.1007/s00268-009-0074-7

31. Sise MJ. Acute mesenteric ischemia. Surg Clin North Am. 2014;94(1):165-181. PMID: 24267504. doi:10.1016/j.suc.2013.10.012

32. Acosta S. Mesenteric ischemia. Curr Opin Crit Care. 2015;21(2):171-178. PMID: 25689121. doi:10.1097/MCC.0000000000000189

33. Clair DG, Beach JM. Mesenteric Ischemia. N Engl J Med. 2016;374(10):959-968. PMID: 26962730. doi:10.1056/NEJMra1503884

34. Kärkkäinen JM, Lehtimäki TT, Saari P, et al. Intestinal fatty acid binding protein (I-FABP) as a prognostic marker in critically ill patients. Biomarkers. 2016;21(8):689-695. PMID: 27193291. doi:10.3109/1354750X.2016.1171907

35. Chiu YH, Huang MK, How CK, et al. D-dimer in patients with suspected acute mesenteric ischemia. Am J Emerg Med. 2009;27(6):975-979. PMID: 19683117. doi:10.1016/j.ajem.2008.07.014

36. Grotelüschen R, Bergmann W, Welte MN, et al. What Predicts Perioperative Mortality in Patients Undergoing Surgery for Acute Mesenteric Ischemia? An Analysis of 95 Patients. J Gastrointest Surg. 2020;24(10):2321-2331. PMID: 31428999. doi:10.1007/s11605-019-04372-0

37. Mastoraki A, Mastoraki S, Tziava E, et al. Mesenteric ischemia: Pathogenesis and challenging diagnostic and therapeutic modalities. World J Gastrointest Pathophysiol. 2016;7(1):125-130. PMID: 26909235. doi:10.4291/wjgp.v7.i1.125

38. Chiu AH, Chan HT, Liu DS, et al. Outcomes of acute mesenteric ischaemia in New South Wales: A state-wide, multicentre study. ANZ J Surg. 2020;90(11):2274-2279. PMID: 32686306. doi:10.1111/ans.16176

---

End of Document

File: /Users/navendugoyal/Desktop/Nav AI Projects /MedVellum/web/content/intensive-care/clinical/gastrointestinal/mesenteric-ischemia.mdx

Metrics:

• Lines: 1,502
• Citations: 38 PubMed references
• Word Count: ~12,500 words

Content Coverage:

• Quick Answer, CICM Exam Focus, Key Points
• Epidemiology, Pathophysiology (detailed vascular anatomy, mechanisms by subtype, ischemia-reperfusion injury)
• Clinical Presentation (by subtype, ICU scenarios)
• Investigations (laboratory, CT angiography protocol, diagnostic algorithm)
• Management (resuscitation, subtype-specific strategies, surgical intervention, post-operative ICU care)
• Complications (early, intermediate, late)
• Prognosis and Outcomes (mortality predictors, long-term outcomes)
• Special Populations (post-cardiac surgery, dialysis, COVID-19, pregnancy, elderly)
• 4 SAQ Practice Questions with comprehensive model answers
• 2 Viva scenarios with examiner questions and expected answers

CICM-Specific Features:

• Emphasis on ICU management (NOMI, post-operative care, hemodynamic optimization)
• Critical care decision-making (second-look laparotomy, damage control surgery)
• Multi-organ support and complications relevant to intensivists
• Evidence-based approach with guideline integration (WSES 2022, ESVS 2017)